The coexistence of Hodgkin lymphoma and myelofibrosis in a patient treated with ruxolitinib

Abstract

Philadelphia-negative myeloproliferative neoplasms are associated with increased risk of lymphoid neoplasms. In this article a female patient with essential thrombocythemia and Hodgkin lymphoma was reported. When remission of lymphoma was obtained secondary myelofibrosis was developed. Therapy with ruxolitinib resulted in resolution of constitutional symptoms and reduction of spleen volume in a short period of time.